Sickle cell-beta-thalassemia disease

Sickle cell-beta-thalassemia disease (also known as sickle cell-beta-thalassemia, hemoglobin S-beta-thalassemia, or HbS/β-thalassemia) is an inherited hemoglobin disorder that results from co-inheritance of one sickle hemoglobin (HbS) gene from one parent and one beta-thalassemia gene from the other parent. It is classified as a sickle cell disease variant and belongs to the group of hemoglobinopathies. The condition primarily affects the blood and vascular system, leading to the production of abnormal hemoglobin that causes red blood cells to become rigid and sickle-shaped, particularly under conditions of low oxygen. This results in chronic hemolytic anemia, vaso-occlusive crises, and progressive organ damage. There are two main subtypes: sickle cell-beta-zero-thalassemia (HbS/β⁰-thal), in which no normal beta-globin is produced, resulting in a clinical picture virtually identical to homozygous sickle cell disease (HbSS); and sickle cell-beta-plus-thalassemia (HbS/β⁺-thal), in which some normal beta-globin is produced, generally leading to a milder clinical course. Key symptoms include recurrent painful vaso-occlusive episodes, chronic anemia, fatigue, jaundice, splenomegaly (particularly in the beta-plus form, as the spleen may be preserved longer than in HbSS disease), acute chest syndrome, stroke, avascular necrosis of bones, and increased susceptibility to infections, especially encapsulated organisms. Over time, patients may develop chronic organ damage affecting the kidneys, lungs, heart, eyes, and bones. Management follows general sickle cell disease treatment guidelines and includes prophylactic penicillin in childhood, vaccination against encapsulated bacteria, folic acid supplementation, adequate hydration, and pain management during vaso-occlusive crises. Hydroxyurea is a key disease-modifying therapy that increases fetal hemoglobin (HbF) levels and reduces the frequency of painful crises, acute chest syndrome, and the need for blood transfusions. Chronic blood transfusion therapy may be indicated for patients with severe complications such as stroke or recurrent acute chest syndrome. L-glutamine and crizanlizumab are newer approved therapies that may reduce the frequency of pain crises. Hematopoietic stem cell transplantation remains the only established curative option and is considered in severe cases, particularly in children with a matched sibling donor. Gene therapy approaches are also under active investigation.

Common questions about Sickle cell-beta-thalassemia disease